Cencora Inc

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of

the Securities Exchange Act of 1934

Filed by the Registrant☒

Filed by a Party other than the Registrant

Check the appropriate box:

☐

Preliminary Proxy Statement

​

☐

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

​

☒

Definitive Proxy Statement

​

☐

Definitive Additional Materials

​

☐

Soliciting Material Pursuant to §240.14a-12

​

Cencora, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

☒

No fee required.

​

☐

Fee paid previously with preliminary materials.

​

☐

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11

​

Dear Cencora shareholders:

On behalf of the Board of Directors, I want to thank you for your continued investment in Cencora.

A new identity

In fiscal 2023, Cencora pursued its purpose of creating healthier futures and executed on its strategy to create long-term, sustainable growth. The Company also rebranded from AmerisourceBergen to Cencora, establishing a unified and inclusive identity for its more than 46,000 team members that better reflects our positive impact on healthcare. The new name signifies our continued evolution to a global organization and underscores our experience and vision in connecting manufacturers, providers, pharmacies, and patients.

Continued execution on strategy

Guided by our purpose, powered by our foundation in pharmaceutical distribution, and differentiated by the breadth of pharmaceutical solutions we provide our partners, throughout fiscal 2023 we advanced our position at the center of healthcare by executing on our strategic imperatives. Key accomplishments included the acquisition of PharmaLex, a leading provider of specialized services for the life sciences industry with operations in over 30 countries, which elevates Cencora’s leadership in specialty services and provides a global platform of pharma manufacturer services capabilities. Additionally, through our investment in OneOncology, a network of leading oncology practices in the United States, we have a unique opportunity to deepen our relationship with community oncologists. Both transactions augment our core businesses and enhance our capabilities, allowing us to create differentiated value for our stakeholders.

Board succession

Over the last year, we continued to prioritize Board succession planning and welcomed Werner Baumann and Lauren Tyler as new independent directors in October 2023. Werner’s and Lauren’s extensive experience at preeminent multinational companies and expertise in their respective fields complement the Board’s existing skill set and further its ability to oversee Cencora’s efforts to achieve long-term, sustainable growth.

As previously announced, Henry McGee will not be standing for re-election at this annual meeting. A valued

member of our Board, Henry has participated in Cencora’s tremendous growth and has contributed immeasurably in his role as a director, including most recently as Chair of the Governance, Sustainability & Corporate Responsibility Committee.

On behalf of the entire Board, I extend our sincere gratitude to Henry for his service. With Henry’s departure, the Board will be comprised of eleven members, nine of whom are independent and five of whom have joined in the last five years.

Continued engagement

We are grateful for your support of the Board and Cencora. The Board remains committed to ongoing dialogue with shareholders and values your input as we continue to evolve our practices and policies. Along with our shareholder engagement efforts, your vote is an important source of feedback. We encourage you to read the information in the proxy statement and the summary annual report in its entirety.

We respectfully request your support for our voting recommendations at the 2024 Annual Meeting of Shareholders, to be held virtually on Tuesday, March 12, 2024, at 4:00 p.m. Eastern Time.

Respectfully submitted,

D. Mark Durcan​

Lead Independent Director

January 29, 2024

​

Notice of 2024 Annual Meeting of Shareholders

Important Notice Regarding the Availability of Proxy Materials for Cencora’s Annual Meeting of Shareholders to be held on March 12, 2024

The Proxy Statement and Annual Report on Form 10-K are available atinvestor.cencora.com andwww.proxyvote.com

Items of business

How to vote

It is important that your shares be represented and voted at the 2024 Annual Meeting. We urge you to vote by using any of the below methods.

By order of the Board of Directors,

Kourosh Q. Pirouz

Senior Vice President, Group General Counsel and Secretary

Conshohocken, Pennsylvania

January 29, 2024

​